PROSPECTS FOR DEVELOPING THE COMPOSITION AND DOSAGE FORM OF A COMBINED ANTIMICROBIAL AND ANTIFUNGAL PREPARATION FOR LOCAL TREATMENT OF SKIN LESIONS IN SOLDIERS
DOI:
https://doi.org/10.32782/3083-7324/2025.2.3Keywords:
antimicrobial drugs, antifungal agents, pharmaceutical market, technology.Abstract
During the full-scale Russian invasion of Ukraine since 2022, there has been an increase in cases of antibiotic-resistant infections, especially in areas of active hostilities. This is due to the military receiving mine and explosive and gunshot wounds during shelling. Such wounds are usually deep and often contaminated with soil, debris, and biological contaminants, mak- ing treatment with standard antimicrobials difficult. Almost always, the wounded are infected with persistent multidrug-resistant pathogens, such as: Methicillin-resistant staphylococcus aureus, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiellapneumoniae, Candida albicans), especially when evacuation occurs hours or even days after the injury, which significantly complicates the treatment of infections, and leads to loss of limbs and sometimes fatalities. The treatment of military personnel with various types of wounds is also complicated by the presence of polymicrobial and complex combined infections with contamination by foreign fragments, which require an integrated approach (antiseptic and surgical treatment). The main drawback of therapy during the treatment of various types of wounds in the military is the insufficient effectiveness of antimicrobial and antifungal drugs, since traditional drugs do not cope due to the resistance of pathogenic strains and, in screening, often turn out to be poorly adapted to the conditions of field hospitals. There is also a problem, namely the lack of protocols for combined antimicrobial and antifungal treatment that would be adapted to combat and field conditions. The need to develop the composition and dosage form of an innovative combined medicinal product exists and remains relevant.
References
1. Белей Н. А., Лоскутов О. А., Строкань А. М., Ізмайлова О. Б. Еволюція мікробіологічного пейзажу ранових інфекцій у військовослужбовців під час повномасштабного вторгнення Росії: ретроспективне когортне дослідження (2022–2024 рр.). Медицина невідкладних станів. 2024. № 20 (7). С. 615–621. DOI: 10.22141/2224-0586.20.7.2024.1767.
2. Di Mambro T., Vanzolini T., Bruscolini P., Perez-Gaviro S., Marra E., Roscilli G., et al. A new humanized antibody is effective against pathogenic fungi in vitro. Scientif ic Reports. 2021. Vol. 11 Art. 19500. DOI: 10.1038/s41598-021-98659-5.
3. Da Silva C., Silveira M., Soares G., De Andrade C., Cabral V., Sa L., et al. Analysis of possible pathways on the mechanism of action of minocycline and doxycycline against strains of Candida spp. resistant to fluconazole. Journal of Medical Microbiology. 2023. Vol. 72 (10). DOI: 10.1099/jmm.0.001759.
4. Фомін О. О., Фоміна Н. С., Ковальчук В. П., Асланян С. А. Мікрофлора сучасної бойової рани та її чутливість до антибіотиків. Частина I. Укр. мед. часопис. 2023. № 3 (155), V–VI. DOI: 10.32471/umj.1680-3051.155.244023.
5. Liu N., Tu J., Huang Y., Yang W., Wang K., Li Z., Sheng C.Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections. Advances in Drug Delivery Reviews. 2023. Vol. 197. Art. 114819. DOI: 10.1016/j.addr.2023.114819.
6. Man L., Brooker C., Ambike R., Gao Z., Thornton P., Do T., Tronci G. Photodynamic, UV-curable and fibre-forming polyvinyl alcohol derivative with broad processability and staining-free antibacterial capability. European Polymer Journal. 2025. Vol. 228. Art. 113794. DOI: 10.1016/j.
eurpolymj.2025.113794.
7. Martinez-Perez D., Guarch-Perez C., Purbayanto M., Choinska E., Riool M., Zaat S., Swieszkowski W. 3D-printed dual-drug delivery nanoparticle-loaded hydrogels to combat antibiotic-resistant bacteria. Int J Bioprint. 2022. Vol. 9 (3). P. 64–79. https://doi.org/10.18063/ijb.683.
8. Lu X., Zhou J., Ming Y., Wang Y., He R., Ruirui H., Li Y., Feng L., Zeng B., Du Y., Wang C. Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects. Acta Pharmaceutica Sinica B. 2025. Vol. 15 (8). P. 3852–3887. DOI: 10.1016/j.apsb.2025.06.013.
9. Ghimire S., Wu Y., Chug M., Brisbois E., Kim K., Mukhopadhyay K. Engineered zwitterion-infused clay composites with antibacterial and antifungal efficacy. Applied Clay Science. 2024. Vol. 248. Art. 107246. DOI: 10.1016/j.clay.2023.107246.
10. Zhang Q., Liu F., Zeng M., Mao Y., Song Z. Drug repurposing strategies in the development of potential antifungal agents. Applied Microbiology and Biotechnology. 2021. Vol. 105. P. 5259–5279. DOI: 10.1007/s00253-021-11407-7.
11. Zhou J., Lu X., He R., Du Y., Zeng B., Feng L., et al. Antifungal immunity: advances in PRR recognition, adaptive responses, and immune-based therapies. Science China Life Sciences. 2025. Vol. 68 (8). P. 2206–2224. DOI: 10.1007/s11427-024-2835-y.
12. Оксенюк О. Є. Розробка складу та технології антисептичних засобів для лікування мікозів і уражень шкіри : автореф. дис. ... канд. фармац. Наук : 15.00.01. Харків, 2020. 25 с.
